VAXICAN, a biotechnology spin-off company of the University of Gdańsk originating from the Intercollegiate Faculty of Biotechnology UG and MUG, developing a modern anti-cancer vaccine platform, has obtained 10.5 million PLN from DeepTech Capital Consortium in a Seed round. The funds will be used to develop preclinical programmes and bring the first two candidates for therapeutic cancer vaccines to clinical readiness.

VAXICAN is developing a cancer vaccine platform based on its proprietary virus-like particle (eVLP) technology and provides advanced next-generation sequencing (NGS) services. Łukasz Rąbalski, Member of the Laboratory of Virus Molecular Biology, is the CEO of VAXICAN. Congratulations!